Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10285017" target="_blank" >RIV/00216208:11110/14:10285017 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.jhep.2014.06.005" target="_blank" >http://dx.doi.org/10.1016/j.jhep.2014.06.005</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jhep.2014.06.005" target="_blank" >10.1016/j.jhep.2014.06.005</a>
Alternative languages
Result language
angličtina
Original language name
Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program
Original language description
Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naive patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4),
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Hepatology
ISSN
0168-8278
e-ISSN
—
Volume of the periodical
61
Issue of the periodical within the volume
5
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
976-983
UT code for WoS article
000343839900004
EID of the result in the Scopus database
—